Zosano Pharma Corporation

128 articles about Zosano Pharma Corporation

• Zosano Pharma Files Voluntary Petition for Relief Under Chapter 11

  6/2/2022

  Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that on June 1, 2022 it filed a voluntary petition for relief under chapter 11 of title 11 (“Chapter 11”) of the United States Bankruptcy Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware.

• Zosano Pharma Reports First Quarter 2022 Financial Results

  5/13/2022

  Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2022.

• Zosano Pharma Provides Corporate Update

  4/29/2022

  Zosano Pharma Corporation, a clinical-stage biopharmaceutical company, provided a corporate update.

• Zosano Pharma Announces Reverse Stock Split Effective TodayZSAN common stock expected to begin trading on a split-adjusted basis on April 12, 2022

  4/11/2022

  Zosano Pharma Corporation today announced that its Board of Directors has approved a 1-for-35 reverse stock split of the company’s common stock.

• 

  FDA Decisions, Direction Shifts Lead to Job Cuts at Athenex, Zosano

  3/18/2022

  Athenex announced that it is scaling its operations by more than 50%, while Zosano Pharma announced that it is reducing its workforce by around 31%.

• Zosano Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results

  3/17/2022

  “We are in discussions with the FDA to determine if there is a viable option to pursue approval of M207 using the currently available clinical data.

• Zosano Pharma Announces Pricing of $15.4 Million Public Offering of Common Stock and Warrants

  2/9/2022

  Zosano Pharma Corporation, a clinical-stage biopharmaceutical company, announced the pricing of its previously announced underwritten public offering of 51,250,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock, at a public offering price of $0.30 per unit.

• Zosano Pharma Announces Proposed Public Offering of Common Stock and Warrants - Feb 08, 2022

  2/8/2022

  Zosano Pharma Corporation, a clinical-stage biopharmaceutical company, announced that it is commencing an underwritten public offering of units consisting of shares of common stock and warrants to purchase common stock.

• 

  Clinical Catch-Up: January 3-7

  1/10/2022

  The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look.

• Zosano Pharma Announces Changes to Board of Directors; Appoints Cross Functional Business Executive Elaine M. Yang

  12/13/2021

  Zosano Pharma Corporation, a clinical-stage biopharmaceutical company, announced changes to its board of directors, including the appointment of Elaine M. Yang.

• Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Nov 30, 2021

  11/30/2021

  Zosano Pharma Corporation, a clinical-stage biopharmaceutical company, announced that the Board of Directors granted a stock option to purchase 220,000 shares of Zosano’s common stock to a new employee as an inducement award.

• Zosano Pharma Announces the Successful Formulation of a COVID-19 Vaccine Candidate on its Microneedle Patch System

  11/17/2021

  Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the successful formulation of a COVID-19 vaccine candidate, obtained from a vaccine developer, utilizing Zosano’s microneedle patch system.

• Zosano Pharma Reports Third Quarter 2021 Financial Results

  11/10/2021

  Zosano Pharma Corporation today announced financial results for the third quarter ended September 30, 2021, as well as business highlights.

• Zosano Pharma Granted Type C Meeting with FDA Regarding NDA Resubmission for M207 Following Preliminary Top-Line Pharmacokinetic Study Results

  10/4/2021

  Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the company has been granted a Type C written response only meeting with the U.S. Food and Drug Administration (“FDA”) regarding the resubmission of the M207 (zolmitriptan transdermal microneedle system) 505(b)(2) New Drug Application (“NDA”) following receipt of preliminary top-line results from the pharmacokinetic (“PK”) study.

• Zosano Pharma to Present at the H.C. Wainwright Virtual Global Investment Conference

  9/2/2021

  Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo, will present a company overview at the H.C. Wainwright Global Investment Conference.

• Zosano Pharma Reports Second Quarter 2021 Financial Results

  8/10/2021

  Zosano Pharma Corporation, a clinical-stage biopharmaceutical company, announced financial results for the second quarter ended June 30, 2021, as well as business highlights.

• Zosano Pharma Announces Issuance of U.S. Patent for Method of Rapidly Achieving Therapeutic Levels with M207 for the Acute Treatment of Migraine

  7/20/2021

  Zosano Pharma Corporation today announced that it has been granted an additional patent covering method of use of M207 with the issuance of U.S. Patent No. 11,058,630 titled Method of Rapidly Achieving Therapeutic Concentrations of Triptans for the Treatment of Migraines .

• Zosano Pharma Announces Publication of Clinical Data Regarding the Long-term use of Qtrypta™ for the Treatment of Acute Migraine in The Journal of Headache and Pain

  5/26/2021

  Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that an article titled, “Long Term Safety, Tolerability, and Efficacy of Intracutaneous Zolmitriptan (M207) in the Acute Treatment of Migraine” was published in The Journal of Headache and Pain.

• Zosano Appoints Industry Veteran, Kathy McGee, to its Board of Directors

  5/25/2021

  Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the appointment of Kathy McGee, an accomplished biopharmaceutical executive, to its board of directors

• Zosano Pharma Reports First Quarter 2021 Financial Results

  5/12/2021

  Zosano Pharma Corporation, a clinical-stage biopharmaceutical company, announced financial results for the first quarter ended March 31, 2021, as well as business highlights.